The company is developing a product portfolio using its Kinoid technology through various self-antigens, which cause autoimmune or inflammatory diseases. Our most advanced product, IFNα Kinoid®, has completed Phase IIb clinical study. Other preclinical products target different forms of allergies including asthma, dermatomyositis and all food allergies.

We are also constantly improving our technological platform in order to respond more effectively to patient expectations and to national and international regulatory agencies (ANSM, EMA, FDA, etc.)